HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Norgine BV

www.norgine.com

Latest From Norgine BV

Germany’s OTC Market in 2018: Online Sees Double-Digit Growth, Bionorica’s Canephron Uno Tops New Launches

Germany's online channel continued to expand to expand in 2018, with OTC product sales via mail-order pharmacy growing almost 10-times faster than through bricks-and-mortar pharmacy. Meanwhile, GSK's Voltaren brand was top-seller through both channels and Bionorica's Canephron Uno was the best-selling launch during the 12 months. 
Health OTC Drugs

Keeping Track: US FDA Approves Novel Tetracyclines Nuzyra And Seysara; Hemlibra Indication Expands

The latest drug development news and highlights from our US FDA Performance Tracker.
Approvals Drug Review

Deal Watch: Gilead Continues To Add To IO Armamentarium In Collaboration With Gadeta

Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.

M & A Deals

Norgine Holds Out Cetilistat Hope As Takeda Alliance Ends In Challenging Japan Market

Takeda and Norgine’s decision to finally end their alliance for cetilistat in Japan, years after the obesity drug was approved in its first potential market, serves as another sign of the sector’s challenges in the country.

Japan Commercial
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Hepatic (Liver)
  • Neurology, Nervous System
  • Alias(es)
  • Norgine International Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Company Type
  • Midsize European
  • Parent & Subsidiaries
  • Norgine BV
  • Senior Management
  • Peter Stein, Chmn. & CEO
    Christopher Bath, CFO
    Paul Pay, Chief Bus. Dev. Officer
    Alastair Benbow, Chief Dev. & Medical Officer
    Kenneth Scrimgeour, Chief Commercial Officer
  • Contact Info
  • Norgine BV
    Phone: (31) 1895 826 600
    Hogehilwig 7
    Amsterdam, 1101 CA
    Netherlands
Advertisement
Advertisement
UsernamePublicRestriction

Register